Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL?
- 1 September 2010
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (5) , 611-619
- https://doi.org/10.1086/655761
Abstract
Background. Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/µL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101–200 cells/µL.Keywords
This publication has 0 references indexed in Scilit: